文献速递神经重症与神经感染认知障碍与痴呆

创伤性脑损伤:预防、临床诊疗与研究方面的进展与挑战

Traumatic brain injury: progress and challenges in prevention, clinical care, and research.
PubMed 文献 · Lancet Neurol · 2022-09-29

创伤性脑损伤(TBI)是常见神经疾病中发病率最高的,并造成重大公共卫生负担;TBI不仅是急性病症,也可作为慢性疾病带来长期后果,包括迟发性神经退行性变风险增加。本文更新2017年《柳叶刀神经病学》委员会报告,讨论在预防、临床诊疗和研究方面的进展与持续及新出现的挑战。

要点

  • 轻性TBI(GCS 13–15分)占就诊TBI病例的90%以上,约50%的成人轻性TBI患者在伤后6个月未恢复至伤前健康水平。
  • 欧洲急诊就诊后出院的TBI患者中,接受随访者不足10%;轻性TBI后结构化随访应被视为良好实践。
  • 目前决定是否行CT检查的效率低下,90–95%的扫描患者无颅内损伤却承受辐射风险;血液生物标志物可辅助临床决策规则。

核心结论

  • TBI是发病率最高的常见神经疾病,造成重大公共卫生负担,且可为慢性疾病并增加迟发性神经退行性变风险。
  • 自2017年委员会报告以来,预防、临床诊疗和研究取得进展,但TBI患者的许多需求仍未得到满足。
  • 低收入和中等收入国家TBI主要由道路交通事故驱动,常涉及摩托车手和行人等弱势道路使用者。
  • 高收入国家大多数TBI由跌倒引起,尤其是65岁及以上老年人,常伴有合并症。

研究设计与样本

  • 本文为对2017年《柳叶刀神经病学》TBI委员会报告的更新,总结预防、临床诊疗和研究方面的进展与挑战。
  • 2017年首份TBI委员会报告呼吁共同努力应对TBI带来的全球健康问题。
  • 2020年11月世界卫生大会通过WHA73.10号决议,呼吁对癫痫和其他神经疾病采取全球行动;WHO于2021年启动道路安全行动十年计划。
  • 国际创伤性脑损伤研究(InTBIR)倡议于2011年成立,作为资助机构合作,推动TBI协作研究并促进全球伙伴参与。

主要发现

  • 脆弱和酒精滥用等风险因素为针对性预防行动提供了机会。
  • 高龄与TBI后更差结局相关,但年龄不应决定治疗限制。
  • 低能量跌倒致伤患者(多为老年人)接受重症监护或急诊干预的可能性较高能量机制致伤者(如道路交通事故)低约50%。
  • 轻性TBI定义为GCS总分13–15分,占就诊TBI病例的大多数(超过90%)。
  • 约50%的成人轻性TBI患者就诊后6个月未恢复至伤前健康水平。

关键数值与推荐

  • 轻性TBI定义为GCS总分13–15分。
  • 欧洲急诊就诊后出院的TBI患者中,接受随访者不足10%。
  • 90–95%的扫描患者无颅内损伤。
  • 正常表现CT扫描的轻性TBI患者血液生物标志物浓度升高提示结构性脑损伤,在高达30%的轻性TBI患者中MR扫描可见。
  • 目前欧洲和美国仅有一家供应商的血液生物标志物检测获监管许可,用于排除疑似TBI患者行CT检查的需要。

临床怎么用

  • 轻性TBI后结构化随访应被视为良好实践。
  • 亟需研究识别哪些轻性TBI患者存在不完全恢复风险。
  • 血液生物标志物检测可增加先前提出的临床决策规则的价值,有望提高效率同时减少辐射暴露。
  • 重症监护中,自动分析血压和颅内压并计算衍生参数有助于个体化管理TBI。
  • 识别可能从特定治疗方式更多获益的患者亚组代表了向精准医学的转变。

局限性

  • 老年患者常被排除在既往临床试验之外,缺乏证据指导其治疗,亟需适当证据。
  • 大多数可用的血液生物标志物检测仅用于研究。
  • 尽管证据积累表明单一生物标志物性能可与组合相当,监管许可仅针对生物标志物组合。
  • 需要跨平台结果 harmonisation。
  • 联邦机器学习需要进一步发展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Traumatic brain injury (TBI) has the highest incidence of all common neurological disorders, and poses a substantial public health burden. TBI is increasingly documented not only as an acute condition but also as a chronic disease with long-term consequences, including an increased risk of late-onset neurodegeneration. The first Lancet Neurology Commission on TBI, published in 2017, called for a concerted effort to tackle the global health problem posed by TBI. Since then, funding agencies have supported research both in high-income countries (HICs) and in low-income and middle-income countries (LMICs). In November 2020, the World Health Assembly, the decision-making body of WHO, passed resolution WHA73.10 for global actions on epilepsy and other neurological disorders, and WHO launched the Decade for Action on Road Safety plan in 2021. New knowledge has been generated by large observational studies, including those conducted under the umbrella of the International Traumatic Brain Injury Research (InTBIR) initiative, established as a collaboration of funding agencies in 2011. InTBIR has also provided a huge stimulus to collaborative research in TBI and has facilitated participation of global partners. The return on investment has been high, but many needs of patients with TBI remain unaddressed. This update to the 2017 Commission presents advances and discusses persisting and new challenges in prevention, clinical care, and research. In LMICs, the occurrence of TBI is driven by road traffic incidents, often involving vulnerable road users such as motorcyclists and pedestrians. In HICs, most TBI is caused by falls, particularly in older people (aged ≥65 years), who often have comorbidities. Risk factors such as frailty and alcohol misuse provide opportunities for targeted prevention actions. Little evidence exists to inform treatment of older patients, who have been commonly excluded from past clinical trials—consequently, appropriate evidence is urgently required. Although increasing age is associated with worse outcomes from TBI, age should not dictate limitations in therapy. However, patients injured by low-energy falls (who are mostly older people) are about 50% less likely to receive critical care or emergency interventions, compared with those injured by high-energy mechanisms, such as road traffic incidents. Mild TBI, defined as a Glasgow Coma sum score of 13–15, comprises most of the TBI cases (over 90%) presenting to hospital. Around 50% of adult patients with mild TBI presenting to hospital do not recover to pre-TBI levels of health by 6 months after their injury. Fewer than 10% of patients discharged after presenting to an emergency department for TBI in Europe currently receive follow-up. Structured follow-up after mild TBI should be considered good practice, and urgent research is needed to identify which patients with mild TBI are at risk for incomplete recovery. The selection of patients for CT is an important triage decision in mild TBI since it allows early identification of lesions that can trigger hospital admission or life-saving surgery. Current decision making for deciding on CT is inefficient, with 90–95% of scanned patients showing no intracranial injury but being subjected to radiation risks. InTBIR studies have shown that measurement of blood-based biomarkers adds value to previously proposed clinical decision rules, holding the potential to improve efficiency while reducing radiation exposure. Increased concentrations of biomarkers in the blood of patients with a normal presentation CT scan suggest structural brain damage, which is seen on MR scanning in up to 30% of patients with mild TBI. Advanced MRI, including diffusion tensor imaging and volumetric analyses, can identify additional injuries not detectable by visual inspection of standard clinical MR images. Thus, the absence of CT abnormalities does not exclude structural damage—an observation relevant to litigation procedures, to management of mild TBI, and when CT scans are insufficient to explain the severity of the clinical condition. Although blood-based protein biomarkers have been shown to have important roles in the evaluation of TBI, most available assays are for research use only. To date, there is only one vendor of such assays with regulatory clearance in Europe and the USA with an indication to rule out the need for CT imaging for patients with suspected TBI. Regulatory clearance is provided for a combination of biomarkers, although evidence is accumulating that a single biomarker can perform as well as a combination. Additional biomarkers and more clinical-use platforms are on the horizon, but cross-platform harmonisation of results is needed. Health-care efficiency would benefit from diversity in providers. In the intensive care setting, automated analysis of blood pressure and intracranial pressure with calculation of derived parameters can help individualise management of TBI. Interest in the identification of subgroups of patients who might benefit more from some specific therapeutic approaches than others represents a welcome shift towards precision medicine. Comparative-effectiveness research to identify best practice has delivered on expectations for providing evidence in support of best practices, both in adult and paediatric patients with TBI. Progress has also been made in improving outcome assessment after TBI. Key instruments have been translated into up to 20 languages and linguistically validated, and are now internationally available for clinical and research use. TBI affects multiple domains of functioning, and outcomes are affected by personal characteristics and life-course events, consistent with a multifactorial bio-psycho-socio-ecological model of TBI, as presented in the US National Academies of Sciences, Engineering, and Medicine (NASEM) 2022 report. Multidimensional assessment is desirable and might be best based on measurement of global functional impairment. More work is required to develop and implement recommendations for multidimensional assessment. Prediction of outcome is relevant to patients and their families, and can facilitate the benchmarking of quality of care. InTBIR studies have identified new building blocks (eg, blood biomarkers and quantitative CT analysis) to refine existing prognostic models. Further improvement in prognostication could come from MRI, genetics, and the integration of dynamic changes in patient status after presentation. Neurotrauma researchers traditionally seek translation of their research findings through publications, clinical guidelines, and industry collaborations. However, to effectively impact clinical care and outcome, interactions are also needed with research funders, regulators, and policy makers, and partnership with patient organisations. Such interactions are increasingly taking place, with exemplars including interactions with the All Party Parliamentary Group on Acquired Brain Injury in the UK, the production of the NASEM report in the USA, and interactions with the US Food and Drug Administration. More interactions should be encouraged, and future discussions with regulators should include debates around consent from patients with acute mental incapacity and data sharing. Data sharing is strongly advocated by funding agencies. From January 2023, the US National Institutes of Health will require upload of research data into public repositories, but the EU requires data controllers to safeguard data security and privacy regulation. The tension between open data-sharing and adherence to privacy regulation could be resolved by cross-dataset analyses on federated platforms, with the data remaining at their original safe location. Tools already exist for conventional statistical analyses on federated platforms, however federated machine learning requires further development. Support for further development of federated platforms, and neuroinformatics more generally, should be a priority. This update to the 2017 Commission presents new insights and challenges across a range of topics around TBI: epidemiology and prevention (section 1); system of care (section 2); clinical management (section 3); characterisation of TBI (section 4); outcome assessment (section 5); prognosis (Section 6); and new directions for acquiring and implementing evidence (section 7). Table 1 summarises key messages from this Commission and proposes recommendations for the way forward to advance research and clinical management of TBI.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Maas AIR, Menon DK, Manley GT, et al. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 2022. PMID: 36183712. doi:10.1016/S1474-4422(22)00309-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。